Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Imperial Brands’ sales go up in steam
Concern that vaping could cause lung-related illnesses and is promoting smoking among children is causing consumers to have second thoughts and has sparked a profit warning at Imperial Brands.
"Investors' hopes for a new lease of life for nicotine have vanished in a cloud of steam," says Karen Kwok for Breakingviews. Growing concern in America that vaping could cause lung-related illnesses and is promoting a smoking "epidemic" among children is causing consumers to have second thoughts. Hence this week's profit warning at Imperial Brands, which wiped 13% off the stock.
The vaping revolution was supposed to be a way for "the deathstick business" to reinvent itself, says Nils Pratley in The Guardian. But talk of unexplained illnesses and a regulatory clampdown mean that the "strategic fog" is thickening. A £100m cut to revenue forecasts this year doesn't sound like much in the context of £7.5bn in overall group revenues, but it raises difficult questions about the future of the industry.
Shares in the firm have halved over the last three years. Yet tobacco investors are largely in it for the generous dividends. Imperial's shareholders have collected about £10bn in payouts in the last nine years.
Start your trial of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
The slump leaves the shares on a 10% dividend yield, notes Jim Armitage in The Evening Standard. Yet management has already said that future payouts will be less generous, and the latest warning raises the prospect of an outright cut.
Was it wise to invest millions in "next-generation" products for which "sales are falling, competition is tough and regulations unpredictable"? Perhaps the firm should just have stuck to selling old-fashioned fags, "paying the big divis" and letting the business "gently decline".
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
